GENE THERAPY–EVOLVED.
THE GENE CODING COMPANY

About Us

SalioGen Therapeutics is advancing potentially curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived.

SalioGen is initially focused on providing durable, safe and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

Leadership

Management

Raymond Tabibiazar, M.D.

Chairman & Chief Executive Officer
Board Chair

Joseph J. Higgins, M.D.

President & Chief Scientific Officer
Board Member

Suku Nagendran, M.D.

Board Member

Sean Stalfort

Board Member

Founding Scientific Advisory Board

Nancy L. Craig, Ph.D.

Chair
Professor Emerita, Johns Hopkins University School of Medicine

Beverly Davidson, Ph.D.

Children’s Hospital of Philadelphia, University of Pennsylvania

Ronald M. Krauss, M.D.

University of California, San Francisco

Ellis J. Neufeld, M.D., Ph.D.

St. Jude Children’s Research Hospital

Jesse Owens, Ph.D.

University of Hawaii

Thomas Quertermous, M.D.

Stanford University School of Medicine

Advisors

Brian Hew, Ph.D.

University of Hawaii

Andrew Knudten M.S., MBA

Jaguar Gene Therapy

Mark Edward Pennesi, M.D. Ph.D.

Casey Eye Institute, Oregon Health & Science University

Renee Ryals, Ph.D.

Casey Eye Institute, Oregon Health & Science University

Gaurav Sahay, Ph.D.

Oregon State University

Troy Short, M.S.

Jaguar Gene Therapy

Wayne Tschetter. Ph.D.

Casey Eye Institute, Oregon Health & Science University

Matthew H. Wilson, M.D., Ph.D.

Vanderbilt University

Jonathan Yen, Ph.D.

St. Jude Children’s Research Hospital

Collaborators

Frederick Dyda, Ph.D.

National Institutes of Health

Alison B. Hickman, Ph.D.

National Institutes of Health

Contact Us

Corporate Inquiries:

Media Inquiries:

Career Inquiries:

Please follow us on Twitter and LinkedIn.

News

Gene therapy 3.0? Gene-coding startup launches with $20M

A new biotech is emerging from stealth to develop what its CEO calls “third-generation gene therapy.”

Founded by former Human Genome Project researcher Joseph Higgins, SalioGen Therapeutics launched Monday with $20 million in Series A funding.

Read More →

SalioGen raises $20M to validate non-viral gene therapy platform

SalioGen Therapeutics has raised $20 million to validate a platform designed to eliminate barriers to the use of gene therapies. The series A will support preclinical validation of mammal-derived enzyme saliogase in the creation of in vivo gene therapies for familial hypercholesterolemia and inherited macular degeneration.

Read More →

Looking to take advantage of ‘silenced’ enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

Gene therapy has made big strides over the years, from the first generation AAV-based therapies to the CRISPR/Cas9 technology that has now taken the scientific world — and Nobel Prize committee — by storm.

Read More →

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy

SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy Introducing a mammal-derived …

Read More →